219 citations
,
October 2009 in “Steroids” 5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.
September 2025 in “Reactions Weekly”
15 citations
,
June 2019 in “Journal of Neuroendocrinology” Isoallopregnanolone may be a safe and effective treatment for reducing tics in a mouse model of Tourette syndrome.
December 2023 in “Reactions weekly” December 2023 in “Reactions weekly” September 2013 in “Reactions weekly” October 2019 in “Asian College of Neuropsychopharmacology” January 2007 in “日本看護学会抄録集 成人看護1” Certain amino acids in 5AR1 and 5AR2 are crucial for binding and resistance to Finasteride.
May 2017 in “Psychiatric news” BPH medications may increase the risk of self-harm and depression, especially in the first 18 months.
11 citations
,
November 2011 in “Neuroreport” Paroxetine relieves pain by increasing allopregnanolone levels.
2 citations
,
September 2025 in “Frontiers in Endocrinology” SARMs show promise but need more evidence to prove they're better than traditional androgens.
1 citations
,
January 2003 in “Expert Opinion on Therapeutic Patents” Steroid sulfatase inhibitors could potentially treat hormone-related disorders like certain cancers, hair loss, acne, and improve cognitive dysfunction.
January 2016 in “Archivio italiano di urologia, andrologia” The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.
February 2026 in “PubMed” Finasteride withdrawal causes anxiety-like behavior in male rats.
April 2018 in “The Journal of Urology” Imipramine and pseudoephedrine treatment can effectively restore normal ejaculation in patients with diabetes, increasing their chances for pregnancy.
5 citations
,
January 2001 in “Advances in protein chemistry” 5α-reductase inhibitors help treat disorders caused by DHT and have potential for future therapies.
2 citations
,
July 2006 in “European Urology Supplements” 5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.
September 2022 in “Reactions Weekly”
December 2023 in “Alzheimer's & Dementia” Long-term use of a drug for hair loss and prostate issues can cause metabolic problems and depression-like behavior in young male rats.
November 2025 in “Drug Testing and Analysis” Epristeride's metabolism involves key metabolites and proteins, affecting its use in doping tests.
5 citations
,
May 2011 in “Movement Disorders” Finasteride may help reduce tic severity in male Tourette syndrome patients.
April 2022 in “Reactions Weekly”
22 citations
,
October 2001 in “Biochemical Pharmacology” GI198745 is more potent and longer-lasting than finasteride, potentially better for treating hair loss.
7 citations
,
April 2021 in “Journal of Clinical Psychopharmacology” Finasteride may increase the risk of depression, anxiety, and suicidal thoughts.
35 citations
,
April 2013 in “Sexual medicine reviews” 5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.
17 citations
,
May 2011 in “Movement Disorders” Finasteride significantly reduced tics and obsessive-compulsive symptoms in patients with Tourette syndrome.
March 2023 in “The Journal of Urology” Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.
15 citations
,
January 2017 in “Experimental Neurology” Finasteride reduces movement issues in Parkinson's disease rats.
24 citations
,
January 1996 in “The Prostate” Finasteride is a safe and effective long-term treatment for prostate enlargement, reducing prostate volume and related symptoms.
9 citations
,
January 2009 in “PubMed” Finasteride treatment can decrease certain steroids and increase others, possibly leading to depression symptoms in some cases.